Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FYBGW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,712
Award facts
- Contract value 100% obligated
- $1,712.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $1,712.23 to DMS Pharmaceutical Group Inc. for the supply of Xolair 300 mg/2 ml auto-injector doses. The contract, effective through September 5, 2025, was issued without a set-aside designation. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Illinois facility. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million and running through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products and medical supplies to support Department of Defense healthcare systems.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, providing prescription medications, biologics, and medical consumables to military health facilities nationwide. Xolair (omalizumab) is a monoclonal antibody medication used primarily for moderate-to-severe allergic asthma treatment. The company has consistently secured contracts with the DLA across diverse pharmaceutical categories, including oncology treatments, vaccines, auto-injectors, and specialty medications, establishing itself as a reliable vendor for supporting military medical supply requirements globally.
Quick answers
Who was awarded contract SPE2DB25FYBGW?
SPE2DB25FYBGW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 14, 2025.
How much is contract SPE2DB25FYBGW worth?
The government has obligated $1,712 on SPE2DB25FYBGW.
Is contract SPE2DB25FYBGW an order under another contract?
Yes. SPE2DB25FYBGW is a delivery order under SPE2DB24D9313, an indefinite delivery contract.
Was contract SPE2DB25FYBGW competed?
The extent of competition for SPE2DB25FYBGW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award